Skip directly to search Skip directly to A to Z list Skip directly to navigation Skip directly to page options Skip directly to site content
Cancer PHGKB

Specific PHGKB|Cancer|PHGKB
Last Posted: Nov 23, 2022
spot light Spotlight

Will Organoids Fill the Gap towards Functional Precision Medicine?
F Papacio et al, J Per Med, November 21, 2022

Precision medicine approaches for solid tumors are mainly based on genomics. Its employment in clinical trials has led to somewhat underwhelming results, except for single responses. Several factors can influence the response, such as gene and protein expression, the coexistence of different genomic alterations or post-transcriptional/translational modifications, the impact of tumor microenvironment. Recently, the introduction of patient-derived organoids (PDOs) (stable primary cultures derived directly from the patient) showed the possibility of using them to predict in vitro the response that should be observed in the patient. This could represent a way to test the effectiveness of a precision medicine approach before administering it to the patient, maximizing clinical benefit.

mRNA revolutionized the race for a Covid-19 vaccine. Could cancer be next?
J Wosen, Stat News, November 21, 2022

The unprecedented success of messenger RNA vaccines against the coronavirus is raising hopes that the technology could lead to new and better vaccines against a much older public health scourge: cancer. In some ways, the challenge is similar: The aim of any vaccine is to focus the immune system’s response against a particular molecule, or antigen, whether that’s a piece of a virus or a protein that coats tumor cells. There’s one important difference, however: Cancer vaccines are generally treatments rather than preventative measures.

Combining PARP Inhibitor With Immunotherapy-Does the Promise of Preclinical Data Translate to Clinic?
Thawani Rajat et al. JAMA oncology 2022 11

Results from two recent trials warrant further investigation into the underlying biology that resulted in lack of clinical benefit of the study drug combination in the majority of patients with non–BRCA-associated cancers, and apparent lack of improved clinical benefit compared with single agent alone in BRCA-associated cancers.

Avelumab Plus Talazoparib in Patients With BRCA1/2- or ATM-Altered Advanced Solid Tumors: Results From JAVELIN BRCA/ATM, an Open-Label, Multicenter, Phase 2b, Tumor-Agnostic Trial.
Schram Alison M et al. JAMA oncology 2022 11

Is the combination of avelumab and talazoparib effective in patients with pathogenic BRCA1/2 or ATM alterations, regardless of tumor type? In this phase 2b nonrandomized controlled trial with 200 patients, neither the BRCA1/2 nor ATM cohort met the prespecified target of an objective response rate of 40% across cancer types. Durable clinical activity was observed in patients with BRCA1/2-associated tumor types (eg, ovarian, breast, prostate, and pancreatic cancers) vs those with non–BRCA-associated cancer types; a notable exception were patients with BRCA1/2-altered uterine leiomyosarcoma, who had prolonged responses to treatment.


news Latest News and Publications
A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population. External Web Site Icon
Heredia David et al. Lung cancer (Amsterdam, Netherlands) 2022 174133-140
Association Between Family History and Risk of Pancreatic Cancer in Patients With BRCA1 and BRCA2 Pathogenic Variants. External Web Site Icon
Shah Ishani et al. Pancreas 2022 51(7) 733-738
Cancer screening and breast cancer family history in Spanish-speaking Hispanic/Latina women in California. External Web Site Icon
Tamayo Lizeth I et al. Frontiers in oncology 2022 12940162
Construction and validation of a prognostic model for lung adenocarcinoma based on endoplasmic reticulum stress-related genes. External Web Site Icon
Li Feng et al. Scientific reports 2022 12(1) 19857
Development and validation of a novel model for predicting the survival of bladder cancer based on ferroptosis-related genes. External Web Site Icon
Li Lianjun et al. Aging 2022 14
Diagnostic accuracy of circulating free DNA testing for the detection of KRAS mutations in non-small cell lung cancer: A systematic review and meta-analysis. External Web Site Icon
Palmieri Maria et al. Frontiers in genetics 2022 131015161
Effectiveness and durability of benefit of mTOR inhibitors in a real-world cohort of patients with metastatic prostate cancer and PI3K pathway alterations. External Web Site Icon
Eule Corbin J et al. Prostate cancer and prostatic diseases 2022
Genitourinary manifestations of Lynch syndrome in the urological practice. External Web Site Icon
Lonati Chiara et al. Asian journal of urology 2022 9(4) 443-450
HER2 amplification by next-generation sequencing to identify HER2-positive invasive breast cancer with negative HER2 immunohistochemistry. External Web Site Icon
Morsberger Laura et al. Cancer cell international 2022 22(1) 350
High Diagnostic Accuracy of Epigenetic Imprinting Biomarkers in Thyroid Nodules. External Web Site Icon
Xu Huixiong et al. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2022 JCO2200232
Identification of a novel signature with prognostic value in triple-negative breast cancer through clinico-transcriptomic analysis. External Web Site Icon
Chen Chao et al. Annals of translational medicine 2022 10(20) 1095
Integrated analysis of the genomic and transcriptional profile of gliomas with isocitrate dehydrogenase-1 and tumor protein 53 mutations. External Web Site Icon
Liu Han-Qing et al. International journal of immunopathology and pharmacology 2022 363946320221139262
Molecular testing for endometrial cancer: An SGO clinical practice statement. External Web Site Icon
Walsh Christine S et al. Gynecologic oncology 2022 16848-55
Multiple mutations in the EGFR gene in lung cancer: a systematic review. External Web Site Icon
Castañeda-González Juan Pablo et al. Translational lung cancer research 2022 11(10) 2148-2163
Next-generation Sequencing as a Potential Diagnostic Adjunct in Distinguishing Between Desmoplastic Melanocytic Neoplasms. External Web Site Icon
Roth Andrew et al. The American journal of surgical pathology 2022
Oncology Informatics for Lynch Syndrome Research and Care: A Literature Review. External Web Site Icon
Dehghani Soufi Mahsa et al. JCO clinical cancer informatics 2022 6e2200087
Predicting the predisposition to colorectal cancer based on SNP profiles of immune phenotypes using supervised learning models. External Web Site Icon
Cakmak Ali et al. Medical & biological engineering & computing 2022
The budget impact of introducing mobocertinib for the postplatinum treatment of advanced non-small cell lung cancer harboring epidermal growth factor receptor exon 20 insertion mutations. External Web Site Icon
Hernandez Luis et al. Journal of managed care & specialty pharmacy 2022 1-15
Extracellular matrix profiles determine risk and prognosis of the squamous cell carcinoma subtype of non-small cell lung carcinoma External Web Site Icon
AL Parker et al, Genome Medicine, November 21, 2022
A comparative cost analysis of two screening strategies for colorectal cancer in Lynch Syndrome in a South African tertiary hospital. External Web Site Icon
Johnson Yasmina et al. Cancer causes & control : CCC 2022
Exploring People's Knowledge of Genetics and Attitude towards Genetic Testing: A Cross-Sectional Study in a Population with a High Prevalence of Consanguinity. External Web Site Icon
Alotaibi Amal et al. Healthcare (Basel, Switzerland) 2022 10(11)
Integrating genome-wide polygenic risk scores and non-genetic risk to predict colorectal cancer diagnosis using UK Biobank data: population based cohort study. External Web Site Icon
Briggs Sarah E W et al. BMJ (Clinical research ed.) 2022 379e071707
Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience. External Web Site Icon
Phan Chinh et al. Therapeutic advances in respiratory disease 2022 1617534666221135324
Lifestyle Behavior Interventions for Preventing Cancer in Adults with Inherited Cancer Syndromes: Systematic Review. External Web Site Icon
Diez de Los Rios de la Serna Celia et al. International journal of environmental research and public health 2022 19(21)
Molecular characterization of early breast cancer onset to understand disease phenotypes in African patients. External Web Site Icon
Tonouo Pamela Derliche et al. Medical oncology (Northwood, London, England) 2022 40(1) 13
Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment. External Web Site Icon
Olivier Timothée et al. BMC medicine 2022 20(1) 392
Non-V600E/K BRAF Mutations in Metastatic Melanoma: Molecular Description, Frequency, and Effectiveness of Targeted Therapy in a Large National Cohort. External Web Site Icon
Girod Manon et al. JCO precision oncology 2022 6e2200075
Racial and ethnic variation in BRCA1 and BRCA2 genetic test results among individuals referred for genetic counseling at a large urban comprehensive cancer center. External Web Site Icon
Abdallah Nadine et al. Cancer causes & control : CCC 2022
Systematic mapping review of guidelines for BRCA1/2 genetic testing globally: investigating geographic and regional disparities in health equity for women and families at risk for hereditary ovarian cancer. External Web Site Icon
Hughes Brittany N et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2022
APOBEC Mutational Signatures in Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancers Are Associated With Poor Outcomes on CDK4/6 Inhibitors and Endocrine Therapy. External Web Site Icon
Sammons Sarah et al. JCO precision oncology 2022 6e2200149

More


Disclaimer: Articles listed in the Public Health Knowledge Base are selected by the CDC Office of Public Health Genomics to provide current awareness of the literature and news. Inclusion in the update does not necessarily represent the views of the Centers for Disease Control and Prevention nor does it imply endorsement of the article's methods or findings. CDC and DHHS assume no responsibility for the factual accuracy of the items presented. The selection, omission, or content of items does not imply any endorsement or other position taken by CDC or DHHS. Opinion, findings and conclusions expressed by the original authors of items included in the update, or persons quoted therein, are strictly their own and are in no way meant to represent the opinion or views of CDC or DHHS. References to publications, news sources, and non-CDC Websites are provided solely for informational purposes and do not imply endorsement by CDC or DHHS.

TOP